Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Consumer Discretionary, Industrials
Tech for Global, Globalization Footprints of the Established and the New
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
AI-driven pharmaceutics Company Helixon Raise CNY 500 Mn in Series A Round
As one of the key players in computational biology, Helixon received recognition from the capital market for its innovation in machine learning algorithms and data acquisition technologies which reconstruct the drug development process and improve the efficiency of new drug development.
Jun 22, 2022 06:13 PM